Outpatient conversion of treatment to potassium-sparing diuretics

Am J Med. 1986 May;80(5):785-8. doi: 10.1016/0002-9343(86)90616-9.

Abstract

Thiazide diuretics frequently cause a decrease in serum potassium levels. In this study, 34 percent of patients taking hydrochlorothiazide had serum potassium levels below 3.5 meq/liter. The response of the serum potassium level was studied after treatment in 56 patients was switched from 50 mg of hydrochlorothiazide daily to either two capsules of hydrochlorothiazide/triampterene (Dyazide), or one tablet of hydrochlorothiazide/amiloride (Moduretic) daily, over nine to 15 months. The 24 patients whose treatment was changed to Dyazide had a rise in serum potassium levels from a mean of 3.56 meq/liter to 4.17 meq/liter in two to three weeks. The 32 patients whose treatment was changed to Moduretic had a rise in serum potassium levels from a mean of 3.76 meq/liter to 4.14 meq/liter in two to three weeks. The resultant rise in potassium levels was stable throughout the follow-up period in both groups. Patient acceptance of this change was excellent.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Ambulatory Care*
  • Amiloride / therapeutic use
  • Antihypertensive Agents / therapeutic use
  • Diuretics / therapeutic use*
  • Drug Combinations / therapeutic use
  • Drug Evaluation
  • Edema / blood
  • Edema / drug therapy
  • Female
  • Humans
  • Hydrochlorothiazide / therapeutic use
  • Hypertension / blood
  • Hypertension / drug therapy
  • Male
  • Middle Aged
  • Potassium / blood*
  • Potassium / therapeutic use
  • Time Factors
  • Triamterene / therapeutic use

Substances

  • Antihypertensive Agents
  • Diuretics
  • Drug Combinations
  • Hydrochlorothiazide
  • hydrochlorothiazide-triamterene
  • amiloride, hydrochlorothiazide drug combination
  • Amiloride
  • Potassium
  • Triamterene